MetaCap

Citius Pharmaceuticals Inc. (CTXR)

NASDAQ: CTXRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.5085+0.0113 (+2.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CTXR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$13.96M
EPS (TTM)
-$1.75
52-week range
0.37 – 1.54
Day range
0.4805 – 0.5136
Volume / Avg
183.70K / 275.44K
Beta
—
Next earnings
Dec 22, 2026

52-week range

$0.37$1.54

CTXR stock today

On Nov 20, CTXR ended the session at $0.5085, adding $0.0113 (2.27%), versus the S&P 500's 3.70% decline. Shares are 67.0% below their 52-week high of $1.54, set on Nov 26, 2025 and 37.4% above the 52-week low of $0.37, near the bottom of the past year's range. CTXR is down 34.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.4%.

Citius Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.75), so its P/E ratio is not meaningful. Citius Pharmaceuticals's next earnings report is expected on Dec 22, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Citius Pharmaceuticals

Company profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Leonard L. Mazur
Headquarters
Cranford, NJ
Employees
23

Financial highlights

Full financials

Citius Pharmaceuticals reported a net loss of $39.7 million, compared with a loss of $39.4 million a year earlier. Diluted earnings per share came in at -$3.38.

Citius Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$90.00K$90.00K
Growth———0.00%0.00%
Net income$-39.74M$-39.43M$-32.54M$-33.64M$-23.05M
EPS (diluted)$-3.38$-5.97$-5.57$-0.23$-0.23

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$4.00+686.63%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 22, 2026
EPS estimate
$-0.41
Last reported (Q3 2026)
Aug 14, 2026
EPS actual vs est.
$-0.34 vs —

CTXR news

All CTXR news

Citius Pharmaceuticals peers

Health Care sector
CTXR peer companies
CompanyPrice% ChgMarket capCompare
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs CTXR
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs CTXR
NCELNewcelX Ltd.2.54-5.58%$14.67Mvs CTXR
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs CTXR
CNTXContext Therapeutics Inc.0.16-5.10%$14.70Mvs CTXR
CELUCelularity Inc. Class A0.463-1.05%$15.02Mvs CTXR
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs CTXR
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs CTXR

Indexes, lists and sector

Citius Pharmaceuticals stock FAQ

What is Citius Pharmaceuticals's stock price today?

CTXR last traded at $0.5085 as of Nov 20, 4:00 PM EST, up 2.27% on the day. Prices are delayed at least 15 minutes.

Does Citius Pharmaceuticals pay a dividend?

No. Citius Pharmaceuticals does not currently pay a regular cash dividend.

When is Citius Pharmaceuticals's next earnings date?

Citius Pharmaceuticals is expected to report earnings on Tuesday, December 22, 2026. Analysts expect EPS of $-0.41.

Who is Citius Pharmaceuticals's CEO?

Mr. Leonard L. Mazur is the chief executive officer of Citius Pharmaceuticals Inc., which has about 23 employees.

Has CTXR ever split its stock?

Yes. The most recent CTXR stock split was a 1-for-25 split on Nov 26, 2024, one of 2 splits on record.

What is the CTXR 52-week high?

The 52-week high for CTXR is $1.54 and the 52-week low is $0.37. The stock is currently 67.0% below its high.

Compare CTXR